Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The Bifunctional Role of Interleukin-1β in Modulating Hepatitis B Virus Replication and Host Defense During HIV/HBV Coinfection

Award Number: F31AI195010
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 02/11/2027
PERIOD OF PERFORMANCE END DATE: 02/10/2028

Group Awards By:

View Award Description

The Bifunctional Role of Interleukin-1β in Modulating Hepatitis B Virus Replication and Host Defense During HIV/HBV Coinfection - PROJECT SUMMARY Hepatitis B virus (HBV) infection remains a major global health burden, affecting 254 million people worldwide and causing over one million deaths annually from cirrhosis and hepatocellular carcinoma. Among people living with HIV, approximately 2.7 million are co-infected with HBV. Despite widespread use of HBV-active antiretroviral therapy, liver-related morbidity and mortality remain disproportionately high. HIV infection is characterized by chronic systemic inflammation and immune dysregulation; however, how this inflammatory environment directly influences HBV replication and liver disease progression remains unclear. Interleukin-1β (IL-1β) is a key inflammatory mediator that is elevated during HIV infection and is strongly induced by microbial translocation via the gut–liver axis, thereby driving ongoing activation of liver-resident immune cells. Previous studies have shown that IL-1β limits early HBV infection by downregulating the viral entry receptor NTCP and activating antiviral host responses. While my initial data confirm these antiviral effects during the early stage of infection, they also reveal a new bifunctional role for IL-1β: treating established HBV infection paradoxically increases viral replication in HepG2-NTCP cells and mouse-passaged primary human hepatocytes, as evidenced by higher levels of intracellular HBV DNA, HBcAg, and HBeAg. Notably, this pro-viral effect can be blocked by inhibition of p38 MAPK, but not NF-κB, indicating a novel non-canonical IL-1β signaling pathway. Based on these findings, I hypothesize that sustained IL-1β exposure, a hallmark of HIV-associated systemic inflammation, enhances HBV replication through p38 MAPK-dependent and NF-κB-independent induction of pro-viral host factors, thereby accelerating liver disease progression in HIV/HBV co-infected individuals. This hypothesis will be tested with two aims: (1) defining the specific post-entry stages of HBV replication that IL-1β enhances, including effects on cccDNA transcription, pgRNA stability, and viral DNA synthesis, using complementary HBV infection and replication models along with physiologically relevant primary hepatocyte–Kupffer cell co-cultures; and (2) identifying the signaling pathway and host factors involved by employing CRISPR-based genetic modifications of key signaling components (RELA and MAPK14), measuring NF-κB pathway activity with reporter assays, and uncovering key candidates through unbiased proteomic profiling of IL-1β-treated MAPK14 knockout versus non- targeting control cells. This work is innovative because it redefines IL-1β from an antiviral cytokine to a context- dependent enhancer of HBV replication during chronic infection. The proposed research will uncover a new mechanism linking HIV-related inflammation to HBV disease progression. It may identify druggable host targets within inflammatory signaling pathways to reduce liver disease burden in HIV/HBV co-infected individuals. This study will provide mechanistic insights into how inflammation promotes viral persistence, supporting my development into an independent researcher focused on viral-host interactions during chronic infections.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $50,114 )
2026	2026	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Allergy and Infectious Diseases Research	000	1	8/11/2026	NEW	$50,114
														Subtotal = $50,114

Grand Total All Awards = $50,114

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Bifunctional Role of Interleukin-1β in Modulating Hepatitis B Virus Replication and Host Defense During HIV/HBV Coinfection

Award Number: F31AI195010

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 02/11/2027

PERIOD OF PERFORMANCE END DATE: 02/10/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer